• EIA projects that crude oil prices will remain high enough to drive U.S. crude oil production to record-high levels in 2023
• The agency observed that crude oil prices have generally increased since April 2020
• Laredo has historically leased 23,739 mineral acres in the Western Williston Basin of Montana
• The company recently purchased 2,361 additional mineral acres, bringing the total Montana leased acres to 26,100

The U.S. Energy Information Agency (“EIA”) is looking for domestic crude oil production to reach record-high levels in the next two years, according to its February 2022 Short-Term Energy Outlook (https://ibn.fm/ZKHa3). Oil and gas exploration and production company Laredo Oil (OTC: LRDC), is in a strong position to benefit from that projected growth as it focuses on acquiring, developing and operating undervalued conventional oil and gas properties in the United States. “In our February 2022 Short-Term Energy Outlook (‘STEO’), we forecast that crude oil prices will remain high enough to drive U.S. crude oil production to record-high levels in 2023, reaching a forecast 12.6 million barrels per day (b/d),” the EIA reported. “In the February STEO, we forecast that U.S. crude oil production will increase to 12.0 million b/d in 2022, up 760,000 b/d from 2021. We forecast that crude oil production in the United States will rise by 630,000 b/d in 2023 to average 12.6 million b/d. We expect more than 80% of that crude oil production growth to come from the Lower 48 states (L48), which does not include production from Alaska and the Federal Offshore Gulf of Mexico.” The agency noted that legacy production, or crude oil production from existing wells, usually decreases rather quickly in tight oil formations, but the agency anticipates that production from new wells will offset these legacy production declines. In addition, EIA observed that crude oil prices have generally increased since April 2020, resulting in increased crude oil production. Laredo is looking to contribute to increased oil production. The company’s strategy involves a focus on unlocking value where others have overlooked it, emphasizing free cash flow that allows the company to seize opportunities quickly and taking a disciplined approach by de-risking projects and exercising care in incurring expenses and allocating capital (https://ibn.fm/D7NHQ). Following this strategy, Laredo has leased 26,100 mineral acres in the Western Williston Basin of Montana; those leases were obtained at favorable prices during the most recent down cycle. Laredo continues to look for undervalued opportunities in the area. The company plans to drill the first development well at one of the first of 10 potential locations it has identified in the coming months, and if that well yields the anticipated results, the company will begin drilling additional wells in the area as soon as practical. The company believes the leased acreage has the potential to yield at least five years of development opportunities. Based in Texas, Laredo Oil is a publicly traded oil and gas exploration and production company. Specializing in conventional and enhanced oil recovery techniques, the company is engaged in the acquisition and development of both undervalued quality conventional oil and gas properties and select mature oil fields. In addition to pursuing conventional recovery methods in target locations, Laredo Oil intends to utilize its proprietary Underground Gravity Drainage(TM) model, where conditions warrant, to profitably recover stranded oil reserves previously thought to be incapable of economic recovery. For more information, visit the company’s website at www.Laredo-Oil.com. NOTE TO INVESTORS: The latest news and updates relating to LRDC are available in the company’s newsroom at https://ibn.fm/LRDC

• The growing popularity of artificial intelligence-enhanced security devices and big data collection are causing a growing revolution in security technology
• Analysts at Research and Markets forecast growth in the global surveillance video market through 2026 at a CAGR of 10.2 percent in response to the evolving technological demands on the sector
• Autonomous security robot developer Knightscope recently went public on the Nasdaq Global Market with its array of models that use advanced technology to patrol and monitor client properties on a 24/7 basis – without human intervention
• A key component of the Knightscope robots’ operational capabilities is the Knightscope Security Operations Center (“KSOC”) that relays data and live-streams 360-degree eye-level video to authorized security professionals

The importance of the security industry’s evolution via the use of artificial intelligence (“AI”) and software analytics is evident in the sector’s market growth. A variety of solutions incorporating technological advances, driven by users’ growing demand for big data and AI functionality, are ushering in a new era of physical security solutions (https://ibn.fm/9XvkG). The rising use of thermal cameras, Internet of Things (“IoT”), and smart city devices, are creating a growing list of opportunities that lead analysts at Research and Markets to predict a CAGR of 10.2 percent for the global surveillance video market between 2021 and 2026, achieving nearly $70 billion in revenues (https://ibn.fm/9aeVK). Autonomous security robot (“ASR”) developer Knightscope (NASDAQ: KSCP) is considered a leading player in intelligent security solutions, employing a variety of stationary and mobile robots to surveil clients’ properties, anticipating potential threats to the clients’ operations, whether in the form of possible crime hazards to personnel or object hazards that may prove destructive to facilities — relaying an array of data back to the security team. While the security robots perform many functions autonomously, the key of the Knightscope technology is the Knightscope Security Operations Center (“KSOC”). This fully functional browser-based user interface provides the managers simple access to real-time data whenever it’s needed to view and interact with the ASRs’ 24/7 flow of data stemming from facial recognition, thermal scans, automatic license plate recognition, video of people’s ingress to select areas, and more (https://ibn.fm/nZYKK). Knightscope’s blog provides a potential scenario in which a general manager can start each workday with a feeling of security. For example, parking areas patrolled by ASRs are no longer occupied by people sleeping in cars or stairwells, and vehicle break-ins have been stopped. Operators can later tap into ASR video feeds to observe that employees are working safely and effectively, while perhaps being warned that a delivery driver is in an unauthorized area. The robot may then patrol a perimeter area and provide reports on its integrity (https://ibn.fm/YSSpL). The scenario anticipates a number of benefits for the company, including increased employee safety and satisfaction that has resulted in fewer costs from worker compensation and wrongful termination lawsuits, fewer costs associated with training new or temporary personnel, fewer costs associated with vandalism or other types of property destruction, and fewer losses to theft. “Robots are deployed to do the monotonous, computational heavy work while the strategic, hands-on activities are the responsibility of the humans,” Knightscope Chairman and CEO William Santana Li stated in a recent news release announcing a strategic partnership with global security and facility services company Allied Universal(TM) (https://ibn.fm/YAUeZ). Huntington Park, California Chief of Police Cosme Lozano successfully encouraged the city council to extend the municipality’s contract with Knightscope last year, stating a robot patrolling a park of concern is “not intended to eliminate or reduce the work of human police officers. It’s simply to enhance our ability to deliver police services. You can think of it if you will as a patrol vehicle, meaning that the patrol vehicle creates that presence and that extension of the police department” (https://ibn.fm/H7S64 – see 20 minute mark). For more information about Knightscope (NASDAQ: KSCP), visit the company’s website at www.Knightscope.com and if you have a need for subscription service you may request a private demonstration of the technology at www.Knightscope.com/demo. NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

• Red White & Bloom Brands is a cannabis and hemp multi-state operator, focused on product consistency and quality, critical to the developing cannabis market that is rapidly growing state by state
• The company’s successes in Michigan, a leading U.S. cannabis market, include the acquisition of full licensing, a 15,000-square-foot manufacturing and distribution facility, and more than 20 new potential locations for cultivation and dispensaries
• In Florida, RWB is building on its acquisition of a 45,000-square-foot cultivation facility to provide premium inventory to several existing dispensaries and new sites expected to open during this year’s Q1

Mainstream wellness consumers have cast sidelong glances at the explosion of cannabidiol (“CBD”) brands over the years, particularly those that require inhalation. But increasing regulatory approval on a state-by-state basis, as well as the 2,000-plus CBD brands that range from easy access “gas station” products to “premium” boutique shop inventory, evidence that the consumer appeal of medicinal cannabis is still showing a significant expansion curve. “While an increasing number of wellness product manufacturers are toying with incorporating CBD and other cannabinoids into products, their efforts have been stymied by the very nature of the ingredients,” Tennessee-based Volunteer Botanicals CEO Derek Odette recently told lifestyle brand Nutritional Outlook (https://ibn.fm/3ABgW). “When cannabinoids and terpenes are extracted from the hemp or marijuana plant, the result is an oil in the same way perfume and cooking oils are extracted from organic materials. Unfortunately, oil-based cannabinoids don’t play well with many nutraceutical ingredients. It can be extremely difficult to balance ratios between different ingredients, which ultimately leads to inconsistent products.” Premium cannabis brand multistate operator Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) has been building assets steadily in Michigan, Florida, Illinois, Massachusetts, and Arizona, while working to establish the quality and consistency wellness consumers seek. After struggling with market perceptions of its business plan at the close of the year, Red White & Bloom announced full licensing for manufacturing both medical and adult use cannabis products in Michigan in January, along with closing a lease assignment for a 15,000-square-foot manufacturing, processing and distribution facility in the city of Warren. “This Warren facility allows us to centralize distribution for our ‘house of premium brands’ in Michigan and finally report all of our Platinum Vape(TM) wholesale sales on a much less confusing and straightforward basis,” CEO and Chairman Brad Rogers stated (https://ibn.fm/wGltC). The manufacturing facility is a key part of RWB’s acquisition strategy for 18 Michigan dispensaries, four cultivation facilities and other important real estate. The company also is using its acquisition of a 45,000-square-foot Florida cultivation facility to spearhead premium inventory production for several existing and new dispensaries under the company’s banner. “The Apopka facility will deliver the cultivation needed to meet our significant retail expansion goals throughout the state. It will also allow us to serve patients with the quality and consistency they deserve,” Rogers stated last fall (https://ibn.fm/er8HJ). “Despite being relatively new players in the Florida market, I feel we have the most talented team of PhDs and horticulturalists, and an incredible grow infrastructure to bring the highest quality products, rich in terpenes and cannabinoid content, to some of the best retail locations in the state starting in Q1 2022,” he added in October. Michigan positioned itself as a leading market in the United States for cannabis sales with $1.79 billion transacted last year. Red White & Bloom’s seed-to-sale integration for the medical and adult use sectors was further enhanced last month when it closed its acquisition of PharmaCo, Inc., granting the company over 20 assets in the state for potential new cultivation and dispensary locations (https://ibn.fm/EbmrU). For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• InnerScope Hearing Technologies has emerged as a leading player in the hearing aid market, including being Walmart’s largest supplier, as part of its large distribution network
• The company has recently launched a new call center free to customers and provides comprehensive services from initial inquiry through lifetime product care
• Management expects the new call center and sales team combined with expansive sales domain to lead to “explosive growth” over the coming 6-12 months

There has been explosive growth in the direct-to-consumer (“DTC”) market, where companies are able to improve margins by eliminating intermediaries and focusing on promoting and selling products straight from the manufacturer to the intended consumer. Thanks to technological advancements, the business strategy has swept across virtually all industries, with innovators like InnerScope Hearing Technologies (OTC: INND) making cutting-edge hearing aids available to people without the need to leave the comfort of their homes. From its headquarters in Roseville, California, InnerScope is emerged as a leading DTC manufacturer and distributor of FDA-registered hearing aids, hearing assistive devices, hearing health-related products, and Personal Sound Amplifier Products (“PSAPs”) dedicated to addressing the global demand for affordable hearing solutions. Simply, the company has broken down barriers that have historically kept millions of people with hearing deficits from utilizing an array of hearing products to improve their quality of life. InnerScope has been building a vertically integrated business model and extensive distribution network that offers its products through major traditional brick-and-mortar retail stores and popular specialized online platforms. The upstart company earned a top spot at Walmart, now the retail juggernaut’s largest hearing aid supplier with displays in 750+ stores in the U.S., in addition to selling through Cardinal Health’s RGH Enterprises and retailers, including Hy-Vee, Giant Eagle, Hartig Drug, Food City and more. In the digital space, InnerScope runs its own online shop at MyHearIQ.com, sells on Amazon.com, and has partnered with FSAstore.com, HSAstore.com, and WellDeservedHealth.com, eCommerce sites catering to consumers enrolled in flexible spending accounts (“FSA”), health saving accounts (“HSA”), and employers’ health incentive programs. Recently, InnerScope widened its services with the launch of its own internal customer call center for the approximately half a million customers of its subsidiary HearingAssist and its iHear hearing aid customers. The launch of the call center (available at 1-800-700-4327) dovetails with the launch of the new HearingAssist.com website. Quality is a hallmark of the InnerScope ecosystem, and the company completed an exhaustive recruitment process to staff its new call center. The new hires are comprised of licensed hearing professionals, doctors of audiology, seasoned customer care specialists, and veteran salespeople, many of which were previously with InnerScope competitors such as Eargo, Hear.com, and YesHearing.com. The bespoke call center is designed for scalability, initially consisting of 15 staffers, with new team members being added each month, according to InnerScope President and CEO Matthew Moore. InnerScope is providing a spate of services free of charge through the call center to ensure the ultimate customer experience beginning with product specialists spending time explaining the different features and benefits of models and products that will best suit the customer’s needs ahead of making a purchase. The suite of services also makes free consultations available with InnerScope’s licensed hearing professionals. These hearing professionals will help customers better understand their hearing issues and assist in proper fittings to maximum benefits. Following the sale, the call center includes After-Care Service Representatives to assist with any questions or concerns throughout the product’s lifetime. “Our new Call Center will allow InnerScope to assume more ownership of the way we approach and deliver a personalized high-touch experience for the customer,” said Moore in a press release on the developments. He concluded, “Our call center is part of our commitment to building industry-leading hearing aid brands backed by superior hi-touch customer service. With our continued product innovation and our ever-growing wholesale/retail partners, including Walmart, we believe there is a tremendous market opportunity for InnerScope to experience explosive growth potential over the next 6 to 12 months.” For more information, visit the company’s website at www.INND.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• Friendable’s Fan Pass Live artist platform and music distribution acquisition, Artist Republik, have achieved the first milestones for integration
• The next phase of growth will include Friendable’s entry into the Metaverse and NFTs
• The global NFT market size reached $50.10 billion in 2021 and is expected to reach $130.35 billion by 2028

Friendable (OTC: FDBL), a mobile technology and marketing company, has announced that phase one of the Fan Pass Live artist platform and Artist Republik integration has been completed. In light of these significant milestones, Friendable has now positioned itself as a full circle offering as the only 360, all-inclusive music artist platform for those artists who wish to maintain control of their art while having access to a support system for development, launches, and monetizing their career. Now, Friendable’s offering includes everything from music development, access to a custom list of curators, and tools to help grow an artist’s fanbase – through livestream, virtual events, ticket sales, and merch development.

One way artists on the platform can generate revenue and attract a wider fanbase is through Fan Pass Live’s monthly contests, with the March edition rewarding the highest number of streams through the Fan Pass app. The top three artists with the highest number of streams during March will win:

• First Place: Choice of any three Artist Pro Services
• Second Place: Choice of any two Artist Pro Services
• Third Place: Choice of one Artist Pro Service
• Bonus: When artists promote three of their streams and tag Fan Pass on Instagram, they will receive a free $10 Grow With Us campaign to add listeners to grow their Spotify or SoundCloud.

Fan Pass Live offers its members exclusive Artist Pro Services that include three categories with three tiers – Artist/Band Logo Design (Basic, Standard, Custom/High Resolution), Merch Design (Basic, Standard, Pro), and Marketing Materials (Basic, Standard, Premium). Grow With Us is available through Artist Republik. It allows artists to market music and accelerates their music careers. Grow With Us is a way to increase engagement on Spotify and SoundCloud by advertising tracks, channels, and playlists through an expansive network.

On the heels of these new milestones being achieved, Friendable is also setting its sights on Metaverse and NFT (non-fungible token) opportunities for both artists and fans. The industry has seen an increased interest in successful crypto integrations that will allow artists to earn more in “days” than they have earned in years – in some cases. Reflecting this growing interest, the global NFT market size reached $50.10 billion in 2021 and is expected to grow at a CAGR of 10.7% during the forecast period of 2021 through 2028. By 2028, experts expect that revenue will reach $130.35 billion (https://ibn.fm/C62rZ).

“Our team’s ability to complete the phase one integration and business combination has been truly amazing. There is always a learning curve when adding anything to an existing business model, and having an existing artist community to introduce new support and services to has to be handled incrementally as well,” Friendable CEO Robert A. Rositano Jr. said (https://ibn.fm/JImsF).

He underlined that the Fan Pass Live team has begun introducing all the additional service offerings that have the independent artist community buzzing about Friendable’s 360 offering or anti-record label solution to build their careers while maintaining control. “Additionally, we are now prepared to turn attention to our next offering expansion with a focus on identifying Metaverse and NFT strategies that can propel our model forward. Partnerships, exclusives, and acquisitions are also part of this strategy,” Rositano Jr. explained.

For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com.

NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Lexaria’s patented DehydraTECH technology proved effective for sildenafil delivery in animal study PDE5-A21-1
• The company also made some notable strides with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD
• By doing so, it hopes to capitalize on the growing cardiovascular drugs market, which is projected to be valued at $107.8 billion by 2025 (https://ibn.fm/LwAUc)
• With the success of its studies thus far, the company seeks to conduct even more trials over the 2022 calendar year

Lexaria Bioscience (NASDAQ: LEXX) has, since its inception, remained committed to enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs. Through its patented DehydraTECH(TM) drug delivery technology that began development in 2014, the company is offering potential solutions for conditions including, but not limited to hypertension, smoking cessation, anti-viral treatments, and other drug classes. In what has marked a landmark achievement for Lexaria, its DehydraTECH technology proved effective for sildenafil delivery in an animal study conducted on lab rats. In addition, the study demonstrated that this technology offered improved treatment of erectile dysfunction, a condition that, according to estimates, will affect about 322 million men worldwide by 2025 (https://ibn.fm/85fJS). When compared to the most common sildenafil product- Viagra, Lexaria’s alternative proved to be more effective, with a delivery of 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation. For reference, Viagra is only moderately bioavailable orally at about 40%, with most people citing its slowness to act as a primary complaint. Lexaria has also made incredible developments with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD. Given the success of previous studies, the company also announced plans for more trials over the year 2022. “During 2021, we completed research & development (‘R&D’) and validating work equal to or greater than all the combined amount previously completed since 2018!” noted Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria. “We have conducted studies across broad areas of interest but also concentrated in specific areas where we have had supportive data,” he added (https://ibn.fm/GH95e). For 2022, the company is focusing on DehydraTECH-processed-CBD for potential heart disease and hypertension treatment. Mr. Bunka also noted that from April (or sooner), the company should kick off what it terms as its largest-ever hypertension study. “If this study is successful, we feel strongly that it will be highly supportive of our IND filing plan, and we will have a clear path toward designing of Phase 1 and even potentially Phase II FDA-registered clinical studies thereunder. Assuming there are no major delays either in study execution or evaluation, we expect full results from this study sometime in Q3, 2022,” noted Mr. Bunka. These strides stamp Lexaria’s position as a global innovator in drug delivery platforms. But, more importantly, they seek to create value for shareholders while also positioning the company for growth as time progresses. Lexaria looks to capitalize on this growth and is, therefore, investing heavily into its R&D to introduce new treatments and receive regulatory approval for existing ones. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Lifescience, biotech, medical device, and healthcare professionals, industry influencers, and health insurance companies are invited to attend DGE’s 8th Advancing Women’s Leadership Skills & Opportunities Conference being held on March 28-30, 2022, as a live streaming event. This conference focuses on shaping and building the career of women entrepreneurs in the health and pharma sectors. The event is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing b2b events. The global event company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries.  Successful business strategies and optimum planning are pivotal for inspiring women professionals who are looking to advance in their career paths. It is the need of the hour as healthcare and pharma companies as more women professionals are becoming a part of the healthcare workplace. This move is particularly important in the evolving medical scenario where women have phenomenal leadership skills that can take them to the top positions within their organizations. The 8th Advancing Women’s conference by DGE will be attended by industry stalwarts, solution providers, venture capitalists and government entities who will discuss the challenges and hurdles that came in their way of reaching the top. They will share insights into their professional journey. Aspiring candidates and new businesses can seek guidance and design business strategies for future expansion. The DGE event will feature such inspiring success stories from top women leaders that will inspire the new genre of industry heads. The Conference focuses on educating, inspiring, and shaping women careers in leadership roles to bridge the gender disparity in the health/pharma industry. The event will kickstart with an introduction from the Chairperson Hani Houshyar, VP, Head of Pipeline Product Development & Commercialization. Participants can learn how to advocate themselves and understand the tactics of self-confidence at the fireside chat events. New women entrepreneurs or those who have been in this field for a while will learn important tips of turning around obstacles to launch pads for success. The virtual event platform will serve as a wonderful avenue for women medical and healthcare professionals for learning to manage their roles as a leader, face work challenges and get maximum productive output. Influential speakers at the DGE conference will share insights showcasing their leadership skills and professional achievements in the medical industry. For more details, please visit https://ibn.fm/tptAf.

• Pluaris is an ideal support application for readers who are gathering information as individuals, members of small teams or parts of large enterprises
• Pluaris mimics the way that humans read, analyze and comprehend textual data
• Pluaris constantly distills knowledge buried in narrative-intensive documents from various data sources, both public and private

Avid readers, who read either because they enjoy it or because they need to gather information to fulfill job tasks or other responsibilities, are often overwhelmed with the sheer volume of information available. Nowigence Inc. (NOWG) has developed an off-the-shelf, cloud-based, artificial intelligence (AI) platform called Pluaris(TM), designed specifically to help these readers handle and organize the mass of material available. When the amount of material that readers want or need to process exceeds their capacity, several things can happen, including fatigue, inability to concentrate or problems recalling information. It is precisely these problems that Pluaris is designed to solve. “Pluaris mimics the way that we, as humans, read, analyze, and comprehend textual data,” the company states (https://ibn.fm/ZN0uy). “Many of us have a backlog of work that requires reading, or face issues with staying focused on the task of reading or recalling the content that we just read. Individuals, teams, and enterprises can now quickly distill knowledge 24/7 buried in narrative-intensive documents instantaneously from various data sources, both public and private.” Nowigence provides a compelling example of the power of Pluaris in connection with the following use case. In March 2020, the White House along with Allen Institute for Artificial Intelligence (“AI2”) uploaded nearly 500,000 scholarly articles including more than 200,000 with full text; these articles discuss COVID-19, SARS-CoV-2 and related coronaviruses. “This freely available dataset was provided to the global research community to apply recent advances in natural language processing and other AI techniques to generate new insights in support of the ongoing fight against the pandemic,” Nowigence noted (https://ibn.fm/ApvVR). The White House and Allen Institute of Artificial Intelligence stated that “there is a growing urgency for these approaches because of the rapid acceleration in new coronavirus literature making it difficult for the medical research to keep up.” According to Nowigence, Pluaris was able to read and analyze the content — it can analyze hundreds of pages in just minutes — extract key intelligence, and answer any question on any topic contained within the knowledge base. “For any reading that it does, it generates an annotated data feed labeling answers to questions on who, what, where, when, why, how, and how much,” the company said. “In addition, it summarizes, provides precise answers to questions asked, analyzes different data perspectives, discovers new connections, creates organized nested notes, and allows teams to work collaboratively by sharing in real-time from anywhere in the world to draw informed conclusions.” Simplifying learning is what Nowigence is all about. Pluaris is an ideal support application for hobby readers and professionals alike, whether they’re reading as individuals or gathering information in small teams or as part of large enterprises. For example, journalists, authors, researchers, analysts and students in higher education could see tremendous benefits from this app, which accesses information and articles found on the web, through digital subscriptions, and in internal documents and transcripts. By integrating state-of-the-art data processing techniques in an intuitive interface at an affordable subscription price, Pluaris puts the power of data science into the hands of consumers. For more information, visit the company’s website at www.Nowigence.com. NOTE TO INVESTORS: The latest news and updates relating to Nowigence are available in the company’s newsroom at https://ibn.fm/NOW

• Flora Growth owns and operates a portfolio of brands offering wholesale products, consumer packaged goods, or pharmaceutical and medical products
• The three-pronged operational approach has allowed the company to substantially expand and accelerate its revenue growth over the short term
• Recently, Flora Growth added yet another brand, JustCBD, to its portfolio; JustCBD’s performance is expected to immediately contribute to FLGC’s 2022 revenues and earnings
• Flora Growth also appointed Jessie Casner as the Chief Marketing Officer; Ms. Casner will lead communications, narrative building, and consumer marketing strategies, in addition to crafting brand awareness activities

Founded on the premise of becoming a global leader in the cannabis trade, Flora Growth (NASDAQ: FLGC) is progressively developing an ecosystem that will support market-leading innovation, all in a mission to build a design-led collective of plant-based wellness and lifestyle brands. The company has expanded rapidly through existing and new brands operating in the cannabis & hemp, food & beverage, skincare & cosmetics, lifestyle & apparel, ancillary & technology, and nutraceuticals & wellness segments. In explaining the motivation behind building a large, ever-growing ecosystem of brands, CEO Luis Merchan recently stated that “as a cannabis company, we need to ensure that we have the ability to penetrate a market with certain categories of products.” And while the segments may appear significant, Luis pointed out, they are simply anchored in three main growth pillars: wholesale products, consumer packaged goods (“CPG”), and pharmaceutical and medical products. “When you look at those three perspectives, you will see that the barriers of entry in each country we are operating in are very different for each of the three [operational pillars]. But this approach has allowed us to dramatically expand and accelerate our revenue growth over the short term,” Luis continued. He was speaking during a presentation delivered at MoneyShow’s Cannabis Investing Virtual Expo held on February 8 (https://ibn.fm/XRnUc). In line with this focus and goal, Flora Growth recently announced it had acquired 100% of the equity interests Just Brand LLC and High Roller Private Label LLC, for a cash consideration of US$16.0 million and 9.5 million privately issued FLGC common shares. JustCBD operates in the consumable cannabinoid market, offering assorted gummies, tinctures, vape cartridges, creams, and more (https://ibn.fm/bYiiq). Following the acquisition, Flora Growth expects JustCBD’s financial performance to immediately contribute to its 2022 revenues and earnings, perfectly exemplifying the highlighted benefit of the three-pronged approach: to expand and accelerate its revenue growth over the short term. Additionally, Flora Growth intends to create major U.S. distribution synergies by linking its existing brand portfolio, including Mind Naturals, Tonino Lamborghini, and Vessel, with JustCBD’s extensive distribution network in the country, thus expanding revenue growth for each of the brands. Flora Growth also intends to offer JustCBD the wherewithal and impetus to expand into international markets where CBD products are legal. This would be a departure from its current focus on the U.S. wellness market. Additionally, FLGC will explore the potential for long-term supply chain efficiencies. “This acquisition continues to strengthen Flora’s foothold in the U.S. wellness market as well as providing meaningful growth acceleration and delivering human capital to the Flora organization. Additionally, there is an incredible opportunity to leverage our economically advantaged cultivation to support the expansion of the JustCBD brand in the global market,” said Luis. He also praised the JustCBD team for its ability to build such a recognizable brand in the noisy, rapid-growth market. Meanwhile, Flora Growth recently appointed Jessie Casner as Chief Marketing Officer. Ms. Casner, who previously held the position of Vice President of Sales and Marketing at Vessel brand, FLGC’s new subsidiary, brings her unmatched experience in go-to-market strategy as well as consumer and brand marketing. In her new role, Ms. Casner will support the rapid growth of Flora Growth’s core CPG brands as well as the company itself by leading the communications, narrative building, and consumer marketing strategies. She will also continue to design FLGC’s brand awareness activities in the consumer and investor markets (https://ibn.fm/bVUlz). For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• In a recent update, InMed Pharmaceuticals president and CEO, Eric A. Adams, lauded the company’s progress and achievements so far, particularly with its product diversification and strategic acquisitions
• Adams noted the company’s commitment to launching more products and executing more programs to continue growing its product portfolio
• InMed also announced the appointment of Gerald (“Jerry”) P. Griffin III as Vice President of Sales and Marketing at BayMedica, its wholly-owned subsidiary

In a conference call and webcast on February 15, 2022, Eric A. Adams, President and Chief Executive Officer of InMed Pharmaceuticals (NASDAQ: INM), emphasized the company’s successful product diversification and strategic acquisition achievements. Most notably, he expressed his optimism regarding the company’s expansion into the health and wellness sector as an ingredient supplier, coupled with the integration of BayMedica’s operations and team into its ongoing activities (https://ibn.fm/VmstM). While noting how recent product launches have allowed the company to top its revenue estimates, Mr. Adams was also keen to point out its ongoing commitment to launch even more products in the coming months. He reiterated the company’s plan to execute more programs designed to grow its market reach, product portfolio, and increase overall growth. “We are committed to further product launches in the immediate term to build out a robust suite of products to meet the needs of the rapidly evolving health and wellness sector,” he noted. “At the same time, our pharmaceutical drug development programs continue to advance in both preclinical and clinical studies and we continue to expand InMed’s intellectual property portfolio, supporting sequential growth opportunities to hit important milestones across all aspects of our business,” he added. Mr. Adams also touched on the company’s commercial initiatives, manufacturing, pharmaceutical development programs, corporate activities, financing activities, and results of operations. He highlighted the ongoing INM-755 clinical study, a Phase 2 clinical trial on the INM-755 cream for the treatment of epidermolysis bullosa that commenced in September 2021. Mr. Adams reiterated that this study, which enrolled up to 20 patients, is expected to be done during the 2022 calendar year. He also touched on the UNM-008 research for the treatment of glaucoma, for which the company is preparing for a pre-investigational New Drug (“PIND”) meeting with the United States Drug Administration (“FDA”) within the coming weeks, and commencement of regulatory applications within the first half of the 2023 calendar year. The corporate update also highlighted the acquisition of BayMedica, which, InMed acknowledges, opens it to multiple advanced manufacturing approaches that afford it the flexibility to select the most cost-effective method to produce rare cannabinoids of interest. To further strengthen its operations on this front, the company has announced the appointment of Gerald (“Jerry”) P. Griffin III as the new Vice president of Sales and Marketing at BayMedica (https://ibn.fm/kHa3n). Mr. Griffin will be responsible for overseeing the commercialization of BayMedica’s health and wellness business, covering both existing products and the launch of new rare cannabinoid alternatives. Mr. Griffin lends his years of experience, having worked in various markets with different cannabinoid products. In addition, he has served in senior positions in multiple companies, including Fortune 500 companies. With that, he brings significant real-world knowledge across the entire value chain to the company. “We are very excited to welcome Jerry to the InMed/BayMedica family. Jerry is joining the team as a strong strategic leader and has the requisite experience to oversee the commercial ramp-up of B2B sales of rare cannabinoids products to the consumer health and wellness market,” noted Shane Johnson, the Senior Vice president (“SVP”) and General Manager of BayMedica. Jerry’s appointment aligns with InMed’s plan to introduce new products in the market, particularly unique high-demand rare cannabinoids. It also reflects its commitment to accelerate its commercial activities and grow its market share in this segment. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM